SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for Multiple Sclerosis

MS RESEARCH SUCCESS STARTS WITH RELIABLE ENDPOINT DATA

Recent scientific advancements have spurred the development and approval of new disease-modifying therapies for multiple sclerosis (MS), but the need for a cure and more effective therapies persists. As one of the earliest enablers of the electronic EDSS (eEDSS), researchers leverage Signant's eCOA expertise as well as our full suite of **clinical research technology solutions and scientific services to generate reliable endpoint data.**

CAPTURE BETTER EDSS DATA, FASTER

Take advantage of our extensively tested electronic EDSS which has proven to increase endpoint data quality, improve clinical reviews, and reduce administration time. For more than ten years, our BYOD-ready eEDSS has set the standard for trouble-free implementation and reliable results.

IMPROVE RATER ACCURACY

Inconsistencies in assessment scoring and administration can lead to difficulties interpreting the data collected. Signant's Rater Training program focuses on qualifying raters and standardizing assessment technique to reduce inter- and intra-rater variability. We can also create a custom training video tailored to the individual needs of each study for use across sites and programs.

MAKE PARTICIPATION EASIER

Simplify the clinical trial experience for patients and sites alike by providing tools like eConsent and Telemedicine. These solutions help reduce unnecessary site visits, improve inter-visit remote collaboration between sites and patients, and help protocol adherence.

MAXIMIZE SUPPLY EFFICIENCY

Our RTSM system helps study teams handle variable dosing schedules and complex medication management requirements for global studies with ease. Our operational and logistics experts help you launch faster, minimize product waste, and implement mid-study amendments efficiently.

WORK WITH OUR MS EXPERTS

Talk through your protocol with our science and medicine experts, who have guided more than 50 recent MS studies. We guide the implementation and administration of EDSS and other assessments, recommend methods to decrease site and participant burdens, and ensure your study generates inspection-ready data.

SAFEGUARD ENDPOINT DATA

Guide investigative staff through proper ClinRO assessment technique using our enhanced clinician ratings platform. Automated scoring as well as built-in edit checks help reduce errors. When paired with PureSignal Analytics, we can proactively monitor COA data in real-time, creating opportunities to mitigate risks before they impact your signal detection.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for people living with multiple sclerosis.

SIGNANT'S MULTIPLE SCLEROSIS CLINICAL TRIAL EXPERIENCE

Phases

I II III IV

44 Languages

5,000 Sites

43 Countries

13,500 Patients

57 Protocols

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

Endpoint Reliability

eConsent & Telemedicine

Scientific Advisory

RTSM

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS